Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tadalafil + SGLT2 inhibitors
- Development stage
- Unknown
- Lead developer
- Kafrelsheikh University
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Tadalafil + SGLT2 inhibitors is a combination therapy being investigated for the treatment of metabolic syndrome, specifically addressing comorbid erectile dysfunction and left ventricular diastolic dysfunction. Tadalafil is a phosphodiesterase-5 (PDE5) inhibitor that promotes vasodilation by increasing cGMP levels, primarily used for erectile dysfunction. SGLT2 inhibitors (such as dapagliflozin or empagliflozin) are a class of medications that inhibit the sodium-glucose cotransporter-2 in the kidneys, reducing glucose reabsorption and providing cardiovascular benefits. This combination aims to leverage the endothelial and microvascular improvements of both agents to improve cardiac and sexual function in patients with metabolic syndrome.
- Other names
- tadalafil plus SGLT2 inhibitors
02
Targets
PDE6 (Phosphodiesterase 6)SGLT2 (Sodium-glucose cotransporter protein subunit 2)PDE5A (Cyclic GMP-specific phosphodiesterase 5A)SLC5A1 (Sodium Glucose Cotransporter 1)PDE11A (Phosphodiesterase 11A)
Beyond the preview
Go deeper on tadalafil + SGLT2 inhibitors.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tadalafil + SGLT2 inhibitors.